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A comparative investigation of anti-Müllerian hormone
(AMH) and various biochemical parameters in patients with
cryptorchidism, oligospermia, or varicocele*
Turan AKDAĞ1, Ali Muhtar TİFTİK1, Levent SARIYILDIZ2

Aim: To investigate the serum AMH and various biochemical parameter levels in patients with cryptorchidism,
oligospermia, or varicocele.
Materials and methods: This study included 100 participants, divided into 5 groups: cryptorchidism (n = 20), varicocele
(n = 20), oligospermia (n = 20), and 2 control groups [control 1, 8-12 years old (n = 20) and control 2, 18-24 years old (n=
20)]. Using the blood samples drawn from both patient and control groups, AMH, testosterone, FSH, LH, and prolactin
parameters were investigated.
Results: AMH values measured were found to be 73.04 ± 44.5 ng/mL and 84.81 ± 59.1 ng/mL in 20 children with
cryptorchidism and 20 healthy children (both groups aged between 8 and 12 years), respectively (P = 0.56). In the present
study, AMH values were found to be 5.19 ± 4.9 ng/mL and 7.66 ± 5.6 ng/mL in 20 patients with oligospermia and 20
healthy individuals (both groups aged between 18 and 24 years), respectively (P = 0.10). AMH values in 20 patients with
varicocele and 20 healthy controls aged between 18 and 24 years were determined to be 7.15 ± 5.8 ng/mL and 7.66 ± 5.6 ng/
mL, respectively (P = 0.82). No significant P values were determined, but the decrease in values was remarkable.
Conclusion: New studies with larger number of participants are needed in order to determinate AMH levels in patients
with varicocele, cryptorchidism, or varicocele for diagnostic criteria.
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Kriptorşit, oligospermi ve varikoselli hastalarda anti-müllerian hormon (AMH) ve
farklı biyokimyasal parametrelerin karşılaştırılması
Amaç: Kriptorşit, oligospermi ve varikosel tanılı hastalarda AMH ve farklı biyokimyasal parametrelerin kıyaslanması
yoluyla değişimin saptanması.
Yöntem ve gereç: Çalışmaya 18-24 yaş arası varikosel (n = 20), oligospermi (n = 20) ile 8-12 yaş arası kriptorşit (n = 20)
hasta grupları; 8-12 yaş arası (n = 20) ve 18-24 yaş arası (n = 20) sağlıklı bireyler kontrol gruplar olarak alındı. Hasta ve
kontrol gruplarından kan örnekleri alınarak AMH, testosteron, FSH, LH, ve prolaktin parametreleri çalışıldı.
Bulgular: Çalışmada pubertal dönemde (8-12 yaş arası) 20 kriptorşitli çocuk ile 20 normal çocuk AMH değerleri sırasıyla 73,04
± 44,5 ng/mL ve 84,81 ± 59,1 ng/mL olarak bulunurken (P = 0,56) postpubertal dönemde (18-24 yaşarası) 20 oligospermili
hasta ile 20 normal birey AMH değerleri sırasıyla 5,19 ± 4,9 ng/mL ve 7,66 ± 5,6 ng/mL (P = 0,10) ve 20 varikoselli hasta ile 20
normal birey AMH değerleri ise sırasıyla 7,15 ± 5,8 ng/mL ve 7,66 ± 5,6 ng/mL (P = 0,82) olarak saptandı.
Sonuç: AMH düzeylerinin belirlenmesine yönelik daha geniş katılımcı ile yapılacak yeni çalışmalarla varikosel, oligospermi
ve kriptorşidik vakalarda serum AMH ölçümünün tanı kriteri olabileceği düşünülmektedir.
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Introduction
Hormonal factors are important diagnostic criteria
in the evaluation of varicocele, cryptorchidism,
and oligospermia because these disorders can lead
to infertility. It is very difficult to determine the
underlying mechanisms of disorders occurring
during fetal, prepubertal, and pubertal periods.
The effects of newly discovered hormones, such as
AMH and inhibin, have been proven in this process.
Therefore, it can be said that recent studies have
concentrated on the newly discovered hormones—
AMH and inhibin—due to their effects on patients
with varicocele, cryptorchidism, or oligospermia.
AMH, previously known as Müllerian inhibiting
substance, belongs to a superfamily of dimeric
glycoproteins, structurally similar to transforming
growth factor-b, activins, and inhibins (1). In the male
fetus, AMH is secreted exclusively by the immature
Sertoli cells in the testes. The main biological function
of AMH is to cause the involution of Müllerian
ducts in male embryos (2). During male sexual
differentiation, AMH inhibits differentiation of the
Müllerian ducts into the uterus, fallopian tubes, and
upper vagina (3). In addition to this principal role of
AMH, its continued postnatal expression supports
the hypotheses that AMH may have other roles,
such as the regulation of gonadal function, testicular
descent, lung development, and suppression of
tumor growth (4). AMH is synthesized as a large
precursor with a short signal sequence followed
by the preprohormone that forms homodimers.
Prior to secretion, the mature hormone undergoes
glycosylation and dimerization to produce a 140 kDa
dimer of identical disulfide-linked subunits (5,6).
Circulating levels of AMH remain high until the
onset of puberty, and then progressively decrease
due to the inhibitory effects of intratesticular
testosterone (7). During puberty, AMH levels decline
with testosterone production. AMH inhibits the
differentiation of mesenchymal cells into Leydig cells
and decreases the expression of several steroidogenic
enzymes (8).
Recent studies indicate that male differentiation
requires the secretion of 3 testicular hormones:
AMH, produced by fetal Sertoli cells, induces the
regression of the Müllerian ducts (9); testosterone,
produced by Leydig cells, promotes the development
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of Wolffian duct derivatives and the masculinization
of the external male genitalia (10); and finally,
insulin-like 3 (Insl3) mediates transabdominal
testicular descent into the scrotum (11). In this
respect, clinical applications of serum AMH assay
include isolated abnormalities of external genitalia,
such as microphallus or cryptorchidism.
AMH is secreted at high levels during the early
period of fetal life. However, the serum AMH
concentration declined after 12 months and stays
within normal limits after pubertal stage (12). If AMH
production in Sertoli cells is insufficient, then some
defects, such as gene mutation and AMH receptor
gene defect, will be encountered (13). AMH plays
critical regulatory roles in the gonadal development
and reproductive fertility (14). Therefore serum
AMH levels may be useful as diagnostic criteria
to determine urological dysfunctions, such as
varicocele, cryptorchidism, and varicocele.
The aim of the study was to determine serum
AMH levels in men with different causes of
urological dysfunctions. We undertook this study to
determine whether the levels of AMH would help in
the identification and evaluation of cryptorchidism,
oligospermia, or varicocele.
Materials and methods
This study was performed in 100 participants, divided
into 5 groups; 20 with cryptorchidism, 20 with
varicocele, 20 with oligospermia, and 20 in control
group 1 (8-12 years old) and 20 in control group 2
(18-24 years old).
None of the patients had exhibited a metabolic
disease before admission. The subjects were selected
from the patients that presented to the urology
department and were diagnosed with oligospermia,
varicocele, or cryptorchidism. The oligospermia
group consisted of subfertile men and were evaluated,
including history and spermiogram, according to
World Health Organization criteria (15). Color
Doppler ultrasonography and pelvic computed
tomography were performed in bilateral varicocele
(grade III) and cryptorchidism groups as clinically
indicated. Varicocele and control groups were selected
from among fertile men. The study was approved by
the ethics committee of Selçuk University Medicine
Faculty, Turkey.
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Blood samples (10 mL) were drawn after a 12-14
h-fasting in the morning. The blood samples were
separated after coagulation. Serum testosterone,
FSH, LH, and prolactin levels were analyzed using
the chemiluminescence method. Serum AMH
was measured by enzyme-linked immunosorbent
assay (ELISA) using the AMH/MIS ELISA kit
(Immunotech-Beckman, Marseilles, France).
Statistical analysis
Statistical analyses were carried out with SPSS
(Version 10.0). The Kruskal Wallis one-way analysis
of variance was used, followed by the MannWhitney U test to evaluate the differences between
control groups (control 1 and 2) and patient groups
(cryptorchidism, oligospermia, and varicocele) (16).
–
Data were expressed as mean ± standard error (X
± SE). Results were considered to be statistically
significant at P < 0.05.

Results
The findings are presented in Tables 1-3. Serum AMH
values were found to be 73.04 ± 44.5 ng/mL and 84.81
± 59.1 ng/mL in 20 children with cryptorchidism and
20 healthy children (both groups aged between 8 and
12 years), respectively.
AMH values were found to be 5.19 ± 4.9 ng/mL
and 7.66 ± 5.6 ng/mL in 20 patients with oligospermia
and 20 healthy individuals (both groups aged
between 18 and 24 years), respectively. AMH values
in 20 patients with varicocele and 20 healthy controls
aged between 18 and 24 years were determined to be
7.15 ± 5.8 ng/mL and 7.66 ± 5.6 ng/mL, respectively.
This study demonstrated that serum AMH levels
of the patient groups were lower than those of the
control groups but the difference was not significant
(P > 0.05).

Table 1. Levels of parameters in cryptorchidism group and control group (1).

n

Control Group (1)
(aged 8-12 years)
–
X ± SE

Cryptorchidism Group
–
X ± SE

P

AMH (ng/mL)

20

84.81 ± 59.1

73.04 ± 44.5

0.56

Testosterone (nmol/L)

20

0.92 ± 1.5

0.91 ± 1.3

0.31

Prolactin (mIU/L)

20

10.26 ± 5.3

13.32 ± 8.4

0.25

FSH (mIU/mL)

20

1.25 ± 1.1

1.79 ± 2.4

0.88

LH (mIU/mL)

20

0.54 ± 0.8

0.74 ± 1.4

0.86

Parameters

Table 2. Levels of parameters in varicocele group and control group (2).

Parameters

n

Control Group (2)
(aged 18-24 years)
–
X ± SE

Varicocele Group
–
X ± SE

P

AMH (ng/mL )

20

7.66 ± 5.6

7.15 ± 5.8

0.82

Testosterone (nmol/L)

20

5.21 ± 2.3

5.24 ± 1.8

0.92

Prolactin (mIU/L)

20

15.88 ± 8.8

16.14 ± 13.3

0.38

FSH (mIU/mL)

20

2.95 ± 1.8

5.20 ± 5.5

0.15

LH (mIU/mL)

20

3.79 ± 2.1

4.38 ± 2.2

0.41
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Table 3. Levels of parameters in oligospermia group and control group (2).

Parameters

n

Control Group (2)
(aged 18-24 years)
–
X ± SE

Oligospermia Group
–
X ± SE

P

AMH (ng/mL)

20

7.66 ± 5.6

5.19 ± 4.9

0.10

Testosterone (nmol/L)

20

5.21 ± 2.3

4.49 ± 2.4

0.34

Prolactin (mIU/L)

20

15.88 ± 8.8

18.44 ± 19.3

0.49

FSH (mIU/mL)

20

2.95 ± 1.8

10.85 ± 12.2

0.05*

LH (mIU/mL)

20

3.79 ± 2.1

5.04 ± 3.8

0.38

Discussion
Male infertility is characterized by particular
multifactorial clinical problems, especially during
the early period of sexual development. It is quite
significant to determine possible defects during this
period. In addition to mediating the crucial aspect
of fetal reproductive tract development, AMH
plays regulatory roles in postnatal development and
gonadal maturation (17). It was concluded that a
disproportionate correlation exists between different
age groups and AMH levels.
Prepubertal period serum AMH levels were
observed to be higher than postpubertal period in
our study (Tables 1 and 2). In a previous study, the
serum AMH level of the cryptorchidism group was
found to be lower (40.04 ± 4.9 ng/mL) compared
with controls (53.46 ± 7.51 ng/mL) (18). These
results are similar with those observed in our study
(Table 1), although the difference was not statistically
significant (P = 0.56).
In terms of serum testosterone levels, the
scores were found to be lowest in children with
cryptorchidism, which is consistent with a previous
study (19).
As shown in Tables 1-3, the levels of testosterone,
prolactin, FSH, and LH were found to be lower in
subjects at the age between 8 and 12 years in both
patient and control groups compared with those at the
age between 18 and 24 years in both patient and control
groups, whereas serum AMH levels were found to be
higher in the former. These results are compatible with
those reported in the literature (20,21).
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In the present study, a decreased serum AMH level
was observed in the oligospermia group compared
with controls. Although no serum AMH levels have
been reported to be determined in oligospermia
group in previous studies (22), low serum AMH levels
were determined in this group in our study (Table 3),
which was not statistically significant (P = 0.10). In
another study, serum AMH levels in varicocele and
control groups were reported as 750 pmol/L and 378
pmol/L, respectively (23). The values in this study are
different from those found in our study. AMH values
in patients with varicocele were determined to be
lower compared to controls but the difference was
not to significant (P = 0.82). Pierik reported very low
serum AMH levels in individuals with abnormal testes
(24). In an experimental study conducted on adult rats
by Sriraman et al., serum AMH levels were observed
to reach high local concentrations in a 4-h period
after the administration of intratesticular injection of
serum AMH. In that study, serum AMH levels and
testosterone concentration rates were 574 ± 60 ng/
mL and 0.7 ± 0.1 ng/mL, respectively (25). It can be
concluded from these results that an injection of AMH
could be beneficial within the prepubertal period.
The presence of AMH type II receptor in the
prostate and the initiation of growth-regulatory
pathways by AMH in prostate cancer cells suggest
that the prostate may be a target tissue for AMH
action (26). Further experimental studies will also
help to determine whether AMH would be of
potential therapeutic benefit in the treatment of
prostate cancer. However, the presence of AMH
type II receptor in the breast and the ability of AMH
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ligand to block proliferation of breast cancer cells
suggest that AMH may have a physiological role in
regulating the proliferation of mammary epithelial

cells (27,28). These points remain unclear and need
to be investigated further.

References
1.

Massague J. The transforming growth factor-beta family. Annu
Rev Cell Biol 1990; 6: 597-641.

16.

Wackerly D, Mendenhall W, Scheaffer RL. Mathematical
Statistics with Applications. USA: Thomson Learn; 2002.

2.

Rajpert-De ME, Jorgensen N, Graem N, Müller J, Cate RL,
Skakkebaek NE. Expression of anti-Müllerian hormone during
normal and pathological gonadal development: association
with differentiation of Sertoli and granulosa cells. J Clin
Endocrinol Metab 1999; 84: 3836-3844.

17.

Lee MM, Misra M, Donahoe PK, MacLaughlin DT. MIS/AMH
in the assessment of cryptorchidism and intersex conditions.
Mol Cell Endocrinol 2003; 211: 91-8.

18.

Demircan M, Akinci A, Mutus M. The effects of orchiopexy on
serum anti-Müllerian hormone levels in unilateral cryptorchid
infants. Pediatr Surg Int 2006; 22: 271–3.

19.

Rey R, Lordereau-Richard I, Carel JC, Barbet P, Cate RL, Roger
M et al. Anti-Müllerian hormone and testosterone serum
levels are inversely during normal and precocious pubertal
development. J Clin Endocrinol Metab 1993; 77: 1220-6.

20.

Yamanaka J, Baker M, Metcalfe S, Hutson JM. Serum levels of
Mullerian inhibiting substance in boys with cryptorchidism. J
Pediatr Surg 1991; 26: 621-3.

21.

Najiba L, Ilene F, Jean-Claude C, Marc R. Inhibin B and AntiMüllerian hormone, but not testosterone levels, are normal
in infants with nonmosaic Klinefelter syndrome. J Clin
Endocrinol & Metabol 2004: 89; 1864-1868.

22.

Baker ML, Metcalfe SA, Hutson JM. Serum levels of Müllerian
inhibiting substance in boys from birth to 18 years, as
determined by enzyme immunoassay. J Clin Endocrinol
Metabol 1990; 70: 11-5.

23.

Trigo RV, Bergadá I, Rey R, Ballerini MG, Bedecarrás P,
Bergadá C et al. Altered serum profile of inhibin B, Pro-alpha C
and anti-Müllerian hormone in prepubertal and pubertal boys
with varicocele. Clin Endocrinol 2004; 60: 758-64.

3.

Rodolfo R. Anti-Müllerian hormone in disorders of sex
determination and differentiation. Arq Bras Endocrinol Metab
2005; 49: 26-36.

4.

AH Lane, PK Donahoe. New insights into Mullerian inhibiting
substance and its mechanism of action. J Endocrinol 1998;
158: 1-6.

5.

Kumar A, Karla B, Patel A, McDavid L, Roudebush WE.
Development of a second generation Anti-Müllerian hormone
(AMH) ELISA. J Immunol Methods 2010; 362: 51-59.

6.

Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J,
Cranfield M, Visser JA et al. Development of a sensitive enzyme
immunoassay for anti-Müllerian hormone and the evaluation
of potential clinical applications in males and females. Clin
Endocrinol 2005; 63: 267-273.

7.

Grinspon RP, Rey RA. Anti-müllerian hormone and sertoli cell
function in pediatric male hypogonadism. Horm Res Paediatr
2010; 73: 81-92.

8.

Josso N, Racine C, di Clemente N, Rey R, Xavier F. The role
of anti-Müllerian hormone in gonadal development. Mol Cell
Endocrinol 1998; 145: 3-7.

9.

Griffin JE, Ojeda S. Textbook of Endocrinology. New York:
Oxford University Press; 1988.

10.

Goodman MH. Basic Medical Endocrinology. 3rd ed. USA:
Elsevier Science; 1988.

24.

11.

Serge N, Luis FP. Hormones in male sexual development.
Genes Dev 2000; 14: 3075-3086.

Pierik FH, Burdorf A, de Jong FH, Weber RF. Inhibin B: a novel
marker of spermatogenesis. Ann Med 2003; 35: 12-20.

25.

V Sriraman, E. Niu, JR Matias, PK. Donahoe, DT MacLaughlin,
MP Hardy et al. Müllerian inhibiting substance inhibits
testosterone synthesis in adult rats. J Androl 2001; 22: 750-8.

12.

13.

Aksglaede L, Sørensen K, Boas M, Mouritsen A, Hagen C,
Jensen R et al. Changes in Anti-Müllerian Hormone (AMH)
throughout the life span: a population-based study of 1027
healthy males from birth (cord blood) to the age of 69 years. J
Clin Endocrinol & Metabol 2010; 95: 5357-5364.
Josso N, Boussin L, Knebelmann B, Nihoul-Fékété C, Picard
JY. Anti-Müllerian hormone and intersex states. Trends
Endocrinol Metabol 1991; 2: 227-233.

14.

Josso N, Racine C, di Clemente N, Rey R, Xavier F. The role
of anti-Müllerian hormone in gonadal development. Mol Cell
Endocrinol 1998; 145: 1-2.

15.

World Health Organization. Laboratory Manual for the
Examination of Human Semen and Semen-Cervical Mucus
Interaction. 4th ed. New York: Cambridge University Press;
1999.

26. Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F,
Pugnière M et al. The anti-Müllerian hormone type II receptor:
insights into the binding domains recognized by a monoclonal
antibody and the natural ligand. Biochem J 2004; 379: 785-93.
27. Kevenaar ME, Themmen AP, Rivadeneira F, Uitterlinden AG,
Laven JS, van Schoor NM et al. A polymorphism in the AMH
type II receptor gene is associated with age at menopause in
interaction with parity. Hum Reprod 2007; 22: 2382-8.
28.

Bédécarrats GY, O’Neill FH, Norwitz ER, Kaiser UB, Teixeira
J. Regulation of gonadotropin gene expression by Mullerian
inhibiting substance. Proc Natl Acad Sci USA 2003; 100: 934853.

415

